



Ifw

MAIL STOP AMENDMENT  
Attorney Docket No. 26430U

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

NISHIBE, et al.

Serial No: 10/519,484

Group Art Unit: 4133

Filed: July 21, 2005

Examiner: PALENIK, Jefferey T.

For: CICLESONIDE-CONTAINING STERILE AQUEOUS SUSPENSION

TRANSMITTAL LETTER

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- 1) Transmittal letter;
- 2) Response to Restriction Requirement.

Please charge any required fee, or credit any overpayment, in connection with this matter to deposit Account No. 14-0112.

Respectfully submitted,  
**The Nath Law Group, PLLC**

Date: November 21, 2007

  
Gary M. Nath  
Registration No. 26,965  
Joshua B. Goldberg  
Registration No. 44,126  
Charles D. Niebylski  
Registration No. 46,116  
Customer No. 34375

**THE NATH LAW GROUP, PLLC**  
112 South West Street  
Alexandria, VA 22314  
Tel: (703) 548-6284  
Fax: (703) 683-8396

JBG/CDN\ROA3.TL.doc



MAIL STOP AMENDMENT  
Attorney Docket No. 26430U

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

NISHIBE, et al.

Serial No: 10/519,484

Group Art Unit: 4133

Filed: July 21, 2005

Examiner: PALENIK, Jefferey T.

For: CICLESONIDE-CONTAINING STERILE AQUEOUS SUSPENSION

RESPONSE TO RESTRICTION REQUIREMENT

MAIL STOP AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This is in response to the Official Action dated October 25, 2007. The one-month shortened statutory period for response expires on November 25, 2007. Accordingly, this Response is timely filed.

REMARKS

Claims 1-9 are pending in the captioned application. The Examiner has indicated that claims 1-9 are subject to restriction and/or election in the following groups:

Group I: Claims 1-3, drawn to aqueous suspension containing Ciclesonide.

Group II: Claims 4-9, drawn to a method of manufacturing said suspension.

The Examiner also provides notice that if the applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder.